Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer

被引：0
作者：
Kim, Jin-Soo [1 ]
Han, Hye-Suk [1 ]
Im, Seock-Ah [1 ]
Oh, Do-Youn [1 ]
Han, Won-Shik [1 ]
Lee, Se-Hoon [1 ]
Kim, Dong-Wan [1 ]
Kim, Tae-You [1 ]
Noh, Dong-Young [1 ]
Bang, Yung-Jue [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [31] Results of intercancer cohort: epidemiologic Brazilian data of women with HER-2 positive metastatic breast cancer treated with trastuzumab as first-line therapy
    Marques, E. Q.
    Franke, F.
    Ishi, L.
    Andrade, C.
    Aquino, N.
    Serrano, S.
    Lessa, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 134 - 134
  • [32] Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)
    Jagiello-Gruszfeld, A.
    Tjulandin, Sergei S.
    Dobrovolskava, N.
    Manikhas, A.
    Pienkowski, T.
    Knott, A.
    DeSilvio, M.
    Oliva, C.
    CANCER RESEARCH, 2009, 69 (02) : 246S - 246S
  • [33] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [34] Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab
    Yeo, B.
    Kotsori, K.
    Mohammed, K.
    Walsh, G.
    Smith, I. E.
    BREAST, 2015, 24 (06) : 751 - 757
  • [35] Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
    ten Tije, AJ
    Smorenburg, CH
    Seynaeve, C
    Sparrebooma, A
    Schothorst, KLC
    Kerkhofs, LGM
    van Reisen, LGPM
    Stoter, G
    Bontenbal, M
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) : 352 - 357
  • [36] Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).
    Bahl, Amit
    Braybrooke, Jeremy
    Bravo, Alicia
    Foulstone, Emily
    Ball, Jessica
    Churn, Mark
    Dubey, Sidharth
    Spensley, Saiqa
    Bowen, Rebecca
    Waters, Simon
    Riddle, Pippa
    Wheatley, Duncan
    Stephens, Peter
    Mansi, Janine
    Bezecny, Pavel
    Madhusudan, Srinivasan
    Verrill, Mark
    Markham, Alison
    Pearson, Sylvia
    Wilson, William
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] WEEKLY EPIRUBICIN AND DOCETAXEL AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER
    D'Ottavio, A.
    Vaccaro, A.
    Belli, F.
    Nunziata, C.
    Meliffi, L.
    Moscetti, L.
    Barduagni, M.
    Sperduti, I.
    Gamucci, T.
    ANNALS OF ONCOLOGY, 2004, 15 : 19 - 19
  • [38] Trastuzumab combined with doublet or single-agent chemotherapy as a first-line treatment for HER2-positive metastatic breast cancer.
    Yu, Yunfang
    Wang, Ying
    Chen, Kai
    Fu, Tuping
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer
    Vorkas, P. A.
    Agelaki, S.
    Poumpouridou, N.
    Kroupis, C.
    Mavroudis, D.
    Stathopoulos, E.
    Georgoulias, V
    Liandou, E. S.
    CANCER RESEARCH, 2009, 69 (24) : 599S - 599S
  • [40] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06) : 661 - 666
12345